Clinical Trials Browser

Lymphoproliferative Disorders × 30 days × Clear all

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT07075185 2026-04-16

inMMyCAR

Phase 1 Recruiting

40 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT04329728 2026-04-15

OPAL

Phase 1/2 Recruiting

144 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00092222 2026-04-14

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2 Active not recruiting

75 enrolled

Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT07308886 2026-04-13

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

Phase 2 Recruiting

55 enrolled

LymphoidSarcoma

Lymphoproliferative Disorders, Sarcoma, Kaposi

NCT00032513 2026-04-08

Genetic Studies of Chronic Active Epstein-Barr Disease

Recruiting

300 enrolled

Lymphoid

Herpes Simplex, Infectious Mononucleosis, Lymphoproliferative Disorders, Virus Diseases, Epstein-Barr Virus Infections

NCT03258567 2026-04-08

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

40 enrolled

Lymphoid

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Phase 2 Active not recruiting

25 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

611 enrolled

Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03922724 2026-03-30

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Phase 2 Recruiting

330 enrolled

Lymphoid

Autoimmune Diseases, Immune System Diseases, Lymphoproliferative Disorders, Opportunistic Infections, Lymphoma, T-Cell, Peripheral

NCT05969821 2026-03-23

CHIS

Not yet recruiting

5,000 enrolled

LymphoidMyeloidOther hematologic neoplasm

VEXAS syndrome, Autoimmune Diseases, Hematologic Diseases, Immune System Diseases, Inflammation, Leukemia, Lymphoma, Lymphoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases